Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy.
Commercial Sponsor
AstraZeneca
Summary
This is a dose escalation and expansion trial, in which eligible patients will be assigned to receive AZD2811 as a single agent (either on Days 1 and 4 of each 28-day cycle or on Days 1, 4, 15 and 18 of each 28 day cycle) or in combination with either azacitidine or venetoclax.